95-23652. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Recombinant Vaccine Against Dengue Virus

[Federal Register Volume 60, Number 185 (Monday, September 25, 1995)]
[Notices]
[Pages 49397-49398]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-23652]



-----------------------------------------------------------------------


DEPARTMENT OF DEFENSE

Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Application Concerning a Recombinant Vaccine 
Against Dengue Virus

AGENCY: U.S. Army Medical Research and Materiel Command, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent Application Serial No. 08/
433,263, entitled ``Recombinant Vaccine Made in E. coli Against Dengue 
Virus'', and filed May 2, 1995. This patent has been assigned to the 
United States Government as represented by the Secretary of the Army.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
Attn: Staff Judge Advocate, Fort Detrick, Frederick, Maryland 21702-
5012.

FOR FURTHER INFORMATION CONTACT:
Mr. John F. Moran, Patent Attorney, [phone] or telefax (301) 
619-7714.

SUPPLEMENTARY INFORMATION: The invention relates to the development of 
a recombinant vaccine for dengue viruses in which gene fragments 
encoding important structural and non-structural proteins were 
expressed in Escherichia coli as fusion proteins with Staphylococcal 
protein A. The Recombinant fusion proteins were purified, analyzed for 
antigenicity, immunogenicity, and their ability to protect mice against 
lethal challenge with live dengue (DEN) viruses. Antigenicity was found 
with anti-DEN polyclonal and monoclonal antibodies. Mice immunized with 
the purified fusion protein made anti-DEN antibodies measured by the 
hemagglutination-inhibition and 

[[Page 49398]]
neutralization tests, and were solidly protected against lethal 
challenge with DEN viruses administered by intracranial inoculation.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 95-23652 Filed 9-22-95; 8:45 am]
BILLING CODE 3710-08-M